Cytori Therapeutics, Inc.
3020 Callan Road
San Diego
California
92121
United States
Tel: 858-458-0900
Fax: 858-200-0951
Website: http://www.cytori.com/
Email: info@cytori.com
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties.
Stock Symbol: CYTX
Stock Exchange: NASDAQ
441 articles about Cytori Therapeutics, Inc.
-
Cytori Therapeutics, headquartered in San Diego, published data from its clinical trial of Adipose-Derived Regenerative Cells (ADRCs) in the journal Urology showing positive results.
-
Cytori Therapeutics Announces Inducement Grants for New Employees - Feb. 12, 2018
2/12/2018
The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company.
-
Cytori Therapeutics: Enrollment Completed in Randomized Clinical Trial of Habeo Cell Therapy for Scleroderma and Impaired Hand Function
1/22/2018
In this investigator-initiated clinical trial supported by Cytori, a total of 40 patients were enrolled among 5 French centers.
-
Cytori Closes Rights Offering for Gross Proceeds of $10M
11/29/2017
The warrants will be exercisable upon stockholder approval to increase our authorized shares of common stock.
-
Cytori Announces Expiration of Oversubscribed Rights Offering
11/27/2017
The subscriptions totaled approximately 17,700 units (approximately 77% oversubscribed), and participants are expected to be reduced pro-rata to the total offering size of 10,000 units.
-
Cytori Reports Reduction in Fibrosis Parameters in Scar Study
11/20/2017
The publication describes a study in which Adipose Derived Regenerative Cells, the active component of Cytori Cell Therapy, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring.
-
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
11/16/2017
The data was presented this week at the American Association of Pharmaceutical Scientists Annual Meeting held in San Diego and the abstract is available online.
-
Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21
11/15/2017
Rights holders will need to exercise their subscription rights prior to that date and time.
-
Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis
11/13/2017
Details of the trial can be assessed at https://clinicaltrials.gov/ct2/show/NCT03269409.
-
Cytori Reports Third Quarter 2017 Business and Financial Results
11/10/2017
Third quarter 2017 net loss was $4.8 million, or $0.14 per share.
-
Cytori Therapeutics' STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress
11/7/2017
The presentation will include a full data analysis, beyond the top-line results previously reported by the company in July and October 2017.
-
Cytori to Webcast Third Quarter Financial Results on November 9 - Nov. 2, 2017
11/2/2017
The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
-
SoCal's Cytori Pink Slips 50% of Workforce in Restructuring
9/5/2017
-
Cytori Reports Second Quarter 2017 Business And Financial Results
8/11/2017
-
Cytori Announces Inducement Grants For New Employees
7/26/2017
-
San Diego's Cytori Plunges Scleroderma Med Flunks Phase III Study
7/24/2017
-
Cytori Receives Key Cell Therapy Patent For Scleroderma
7/6/2017
-
Cytori Partners With myTomorrows For Managed Access Program For Europe, Middle East And Latin America
6/14/2017
-
Long Term Safety Data Published On Cytori Technology For Breast Reconstruction After Oncologic Surgery & Radiation Therapy
6/8/2017
-
Cytori To Introduce Next-Generation Celution Technology
6/1/2017